Article
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Gynecologic oncology - 1 Sept 2022
Cadoo Karen, Simpkins Fiona, Mathews Cara, Liu Ying L, Provencher Diane, McCormick Colleen, ElNaggar Adam C, Altman Alon D, Gilbert Lucy, Black Destin, Kabil Nashwa, Bennett James, Munley Jiefen, Aghajanian Carol
Abstract excerpt
OBJECTIVE: Olaparib treatment resulted in significant improvement in objective response rates (ORRs) and progression-free survival (PFS) over non‑platinum chemotherapy in patients with BRCA1/BRCA2-mutated (BRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) and ≥2 prior lines of platinum-based chemotherapy in the phase III SOLO3 study. LIGHT (NCT02983799) prospectively evaluated olaparib treatment for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.